Global Cholesterol-Lowering Drugs Market 2017-2027 : Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs

コレステロール低下薬の世界市場2017-2027

◆タイトル:Global Cholesterol-Lowering Drugs Market 2017-2027 : Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs
◆商品コード:VGAIN7081119
◆調査・発行会社:visiongain
◆発行日:2017年8月
◆ページ数:181
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Sigle User(1名閲覧)GBP2,499 ⇒換算¥374,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

visiongain社が発行した当調査レポートでは、コレステロール低下薬の世界市場について調査・分析し、コレステロール低下薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
・レポートの概要
・イントロダクション
・コレステロール低下薬の世界市場
 (市場規模予測、市場動向、市場の成長要因・阻害要因など)
・コレステロール低下薬の世界市場:セグメント別市場分析
・コレステロール低下薬の世界市場:地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

The global cholesterol-lowering drugs market is expected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is estimated at $19.2bn in 2017. In the Statins and Fixed-Dose Combinations segment, Crestor was on the lead in 2016 and held a share of 26.7%.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 181-page report you will receive 89 tables and 107 figures – all unavailable elsewhere.

The 181-page report provides clear detailed insight into the global cholesterol-lowering drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

• Global Cholesterol-Lowering Drugs market forecasts from 2017-2027

• This report also breaks down the revenue forecast from 2017-2027 for the global cholesterol-lowering drugs market by its main segments:
• Statins and Fixed-Dose Combinations
• Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates
• PCSK9 Inhibitors
• Novel Cholesterol-Lowering Drugs

• This report provides revenue forecast from 2017-2027 for the leading drugs under the Statins and Fixed-Dose Combination segment:
• Crestor
• Lipitor
• Livalo
• Lescol/Lescol XL
• Zocor
• Vytorin
• Caduet
• Others

• This report provides revenue forecast from 2017-2027 for the leading drugs under the Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates segment:
• Zetia
• Welchol
• Tricor
• Others

• This report provides revenue forecast from 2017-2027 for the leading drugs under the PCSK9 Inhibitor segment:
• Praluent
• Repatha
• RN316
• Others

• This report provides revenue forecast from 2017-2027 for the leading drugs under the novel cholesterol-lowering drugs segment:
• Juxtapid
• Kynamro
• MK-0859
• Others

• This report provides individual revenue forecasts to 2027 for these regional and national markets:
• North America: the US, Canada, Mexico
• South America: Brazil, Argentina, Paraguay, Bolivia, Rest of South America
• Europe: Germany, France, the UK, Spain, Italy, Rest of Europe
• Asia-Pacific: Japan, China, India, Australia, Thailand, Rest of APAC
• RoW: Middle East, Africa, Other Countries


• Our study provides SWOT and Porter’s Five Forces analysis that influence the global cholesterol-lowering drugs market

• Our study discusses the selected leading companies that are the major players in the cholesterol-lowering drugs market:
• AstraZeneca
• Merck & Co
• Pfizer
• Kowa Company
• Daiichi Sankyo
• AbbVie
• Novartis
• Sanofi
• Amgen
• Bristol-Myers Squibb (BMS)

【レポートの目次】

1. Report Overview
1.1 Global Cholesterol-Lowering Drugs Market Overview
1.2 Research Methodology
1.2.1 Primary Research
1.2.2 Secondary Research
1.2.3 Market Evaluation & Forecasting Methodology
1.3 Global Cholesterol-Lowering Drugs Market Segmentation
1.4 Why You Should Read This Report
1.5 How this report delivers?
1.6 Key Questions Answered by This Analytical Report
1.7 Frequently Asked Questions (FAQ)
1.8 Who is This Report For?
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Cholesterol-Lowering Drugs
2.1 The Pharmaceutical Industry: A Brief Overview
2.2 Cholesterol: An Essential Lipid
2.3 The Functions of Cholesterol
2.4 Metabolism and Circulation of Cholesterol
2.5 The Role of Cholesterol in Heart Disease
2.6 The Role of Cholesterol in Heart Disease: The Orthodoxy
2.6.1 The IMPROVE-IT Study
2.7 The Role of Cholesterol in Heart Disease: The Controversy
2.8 Raising HDL Cholesterol: A Worthwhile Aim?
2.9 Causes of Hypercholesterolaemia
2.9.1 Atherosclerosis
2.9.2 Dyslipidaemia, Hyperlipidaemia and Hyperlipoproteinaemia
2.9.3 Familial Hypercholesterolaemia
2.10 Treatment of Hypercholesterolaemia
2.10.1 UK Treatment Guidelines for Hypercholesterolaemia
2.10.2 US Treatment Guidelines for Hypercholesterolaemia
2.10.3 Lifestyle Changes
2.10.4 Drugs to Lower Cholesterol
2.10.5 Other Therapeutic Approaches
2.10.5.1 Partial Ileal Bypass: An Outdated Surgical Treatment
2.10.5.2 LDL Apheresis: Directly Removing Cholesterol
2.10.5.3 Liver Transplantation for Familial Hypercholesterolaemia

3. Global Cholesterol-Lowering Drugs Market Forecast 2017 – 2027
3.1 Global Cholesterol-Lowering Drugs Market by Type, 2017-2027
3.2 Cholesterol-Lowering Drugs Market: Statins and Fixed Dose Combination, 2017-2027
3.3 Cholesterol-Lowering Drugs Market: Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs, 2017-2027
3.4 Cholesterol-Lowering Drugs Market: PCSK9 Inhibitors, 2017-2027
3.5 Cholesterol-Lowering Drugs Market: Novel Drugs, 2017-2027

4. Global Cholesterol-Lowering Drugs Market Segments, by Type: Market Forecast 2017 – 2027
4.1 Overview
4.2 Statins and Fixed-Dose Combinations Market Forecast 2017 – 2027
4.3 Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Market Forecast 2017 – 2027
4.4 PCSK9 Inhibitors Market Forecast 2017 – 2027
4.5 Novel Cholesterol-Lowering Drugs Market Forecast 2017 – 2027

5. Global Statins and Fixed-Dose Combinations for Cholesterol-Lowering Drugs Market by Product: Market Forecast 2017 – 2027
5.1 Overview
5.2 Crestor Market Forecast 2017 – 2027
5.3 Lipitor Market Forecast 2017 – 2027
5.4 Livalo Market Forecast 2017 – 2027
5.5 Lescol /Lescol XL Market Forecast 2017 – 2027
5.6 Zocor Market Forecast 2017 – 2027
5.7 Vytorin Market Forecast 2017 – 2027
5.8 Caduet Market Forecast 2017 – 2027
5.9 Others Market Forecast 2017 – 2027
6. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market by Product: Market Forecast 2017 to 2027
6.1 Overview
6.2 Zetia Market Forecast 2017 – 2027
6.3 Welchol Market Forecast 2017 – 2027
6.4 Tricor Market Forecast 2017 – 2027
6.5 Others Market Forecast 2017 – 2027

7. Global PCSK9 Inhibitors for Cholesterol-Lowering Drug Market by Product: Market Forecast 2017 – 2027
7.1 Overview
7.2 Praluent Market Forecast 2017 – 2027
7.3 Repatha Market Forecast 2017 – 2027
7.4 RN316 Market Forecast 2017 – 2027
7.5 Others Market Forecast 2017 – 2027

8. Global Novel Cholesterol-Lowering Market Forecast by Product: Market Forecast 2017 – 2027
8.1 Overview
8.2 Juxtapid Market Forecast 2017 – 2027
8.3 Kynamro Market Forecast 2017 – 2027
8.4 MK-0859 Market Forecast 2017 – 2027
8.5 Other Market Forecast 2017 – 2027

9. Regional and National Cholesterol-Lowering Drugs Market Forecasts 2017 – 2027
9.1 Regional Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.2 North American Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.2.1 USA Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.2.2 Canada Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.2.3 Mexico Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.3 South America Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.3.1 Brazil Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.3.2 Argentina Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.3.3 Paraguay Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.3.4 Bolivia Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.3.5 Rest of South America Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.4 European Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.4.1 France Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.4.2 Germany Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.4.3 UK Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.4.4 Spain Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.4.5 Italy Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.4.6 Rest of Europe Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.5 Asia-Pacific Cholesterol-Lowering Drugs Market Forecast 2017-2027
9.5.1 China Cholesterol-Lowering Drug Market Forecast 2017-2027
9.5.2 Japan Cholesterol-Lowering Drug Market Forecast 2017-2027
9.5.3 India Cholesterol-Lowering Drug Market Forecast 2017-2027
9.5.4 Australia Cholesterol-Lowering Drug Market Forecast 2017-2027
9.5.5 Thailand Cholesterol-Lowering Drug Market Forecast 2017-2027
9.5.6 Rest of APAC Cholesterol-Lowering Drug Market Forecast 2017-2027
9.6 Rest of World Cholesterol-Lowering Drug Market Forecast 2017-2027
9.6.1 Middle East Cholesterol-Lowering Drug Market Forecast 2017-2027
9.6.2 Africa Cholesterol-Lowering Drug Market Forecast 2017-2027
9.6.3 Other countries Cholesterol-Lowering Drug Market Forecast 2017-2027

10. Cholesterol-Lowering Drug Market, Qualitative Analysis, 2017-2027
10.1 Strengths
10.1.1 Strong Pipeline
10.1.2 High Profile Encouraging Healthcare Provision
10.2 Weaknesses
10.2.1 Increasing Generic Penetration
10.2.2 Approved Indications Limited for New Products
10.3 Opportunities
10.3.1 Increasing Prevalence in Emerging Markets
10.3.2 Possible Additional Indications
10.4 Threats
10.4.1 Patent Expiry
10.4.2 Cost-Containment
10.5 Porter’s Five Forces Analysis of the Cholesterol-Lowering Drugs Market
10.5.1 Rivalry among Competitors [High]
10.5.2 Threat of New Entrants [Medium]
10.5.3 Power of Suppliers [Low]
10.5.4 Power of Buyers [Medium]
10.5.5 Threat of Substitutes [High]

11. Leading Companies in the Cholesterol Lowering Drugs Market
11.1 AstraZeneca Plc
11.1.1 AstraZeneca Plc: Company Overview
11.1.2 AstraZeneca Plc: Product Portfolio
11.1.3 AstraZeneca Plc: Recent Developments
11.2 Merck & Co. Inc.
11.2.1 Merck & Co. Inc.: Company Overview
11.2.2 Merck & co. Inc.: Product Portfolio
11.2.3 Merck & Co. Inc.: Recent Developments
11.3 Pfizer Inc.
11.3.1 Pfizer Inc.: Company Overview
11.3.2 Pfizer Inc.: Product Portfolio
11.3.3 Pfizer Inc.: Recent Developments
11.4 Kowa Company, Ltd.
11.4.1 Kowa Company, Ltd.: Company Overview
11.4.2 Kowa Company, Ltd.: Product Portfolio
11.4.3 Kowa Company, Ltd.: Recent Developments
11.5 Daiichi Sankyo Co., Ltd.
11.5.1 Daiichi Sankyo Co., Ltd.: Company Overview
11.6 AbbVie Inc.
11.6.1 AbbVie Inc.: Company Overview
11.6.2 AbbVie Inc.: Product Portfolio
11.7 Novartis AG
11.7.1 Novartis AG: Company Overview
11.7.2 Novartis AG: Product Portfolio
11.7.3 Novartis AG: Recent Developments
11.8 Sanofi S.A.
11.8.1 Sanofi S.A.: Company Overview
11.8.2 Sanofi S.A.: Product Portfolio
11.8.3 Sanofi S.A: Recent Developments
11.9 Amgen Inc.
11.9.1 Amgen Inc.: Company Overview
11.9.2 Amgen Inc.: Product Portfolio
11.9.3 Amgen Inc.: Recent Developments
11.10 BRISTOL-MYERS SQUIBB
11.10.1 Bristol-Myers Squibb: Company Overview
11.10.2 Bristol-Myers Squibb: Product Portfolio

12. Conclusions
12.1 Leading Regional Markets: 2017-2027
12.2 Current Leading Segments: 2017-2027
12.3 World Cholesterol-Lowering Drugs Market: Market Driving Factors

Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form

List of Tables
Table 3.1. Global Cholesterol-Lowering Drugs Market Forecast ($m, AGR%, CAGR%) 2017-2027
Table 4.1. Global Cholesterol-Lowering Drugs Market Segments, by Type ($m, AGR%, CAGR%) 2017-2027
Table 4.2. Global Statins and Fixed-Dose Combinations for Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 4.3. Global Statins and Fixed-Dose Combinations for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($m, AGR%, CAGR%) 2017-2027
Table 4.4. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other for Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 4.5. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($m, AGR%, CAGR%) 2017-2027
Table 4.6. Global PCSK9 Inhibitors for Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 4.7. Global PCSK9 Inhibitors for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($m, AGR%, CAGR%) 2017-2027
Table 4.8. Global Novel Cholesterol-Lowering Drugs for Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 4.9. Global Novel Cholesterol-Lowering Drugs for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($m, AGR%, CAGR%) 2017-2027
Table 5.1. Global Statins and Fixed-Dose Combinations Market by Product($m, AGR%, CAGR%) 2017-2027
Table 5.2. Global Crestor Market Forecast ($m, AGR%, CAGR%) 2017-2027
Table 5.3. Global Lipitor Market Forecast ($m, AGR%, CAGR%) 2017-2027
Table 5.4. Global Livalo Market Forecast ($m, AGR%, CAGR%) 2017-2027
Table 5.5. Global Lescol /Lescol XL Market Forecast ($m, AGR%, CAGR%) 2017-2027
Table 5.6. Global Zocor Market Forecast ($m, AGR%, CAGR%) 2017-2027
Table 5.7. Global Vytorin Market Forecast ($m, AGR%, CAGR%) 2017-2027
Table 5.8. Global Caduet Market Forecast ($m, AGR%, CAGR%) 2017-2027
Table 5.9. Global Others Market of Statins and Fixed-Dose Combinations Segment ($m, AGR%, CAGR%) 2017-2027
Table 6.1. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market by Product ($m, AGR%, CAGR%) 2017-2027
Table 6.2. Global Zetia Market Forecast ($m, AGR%, CAGR%) 2017-2027
Table 6.3. Global Welchol Market Forecast ($m, AGR%, CAGR%) 2017-2027
Table 6.4. Global Tricor Market Forecast($m, AGR%, CAGR%) 2017-2027
Table 6.5. Global Others Market of the Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Segment ($m, AGR%, CAGR%) 2017-2027
Table 7.1. Global PCSK9 Inhibitors Market by Product ($m, AGR%, CAGR%) 2017-2027
Table 7.2. Global Praluent Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 7.3. Global Repatha Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 7.4. Global RN316 Market Forecast ($m, AGR%, CAGR%) 2017-2027
Table 7.5. Global Others Market of the PCSK9 Inhibitors Segment ($m, AGR%, CAGR%) 2017-2027
Table 8.1. Global Novel Cholesterol-Lowering Drugs by Product ($m, AGR%, CAGR%) 2017-2027
Table 8.2. Global Juxtapid Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 8.3. Global Kynamro Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 8.4. Global MK-089 Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 8.5. Global Other Drugs Market of the Novel Cholesterol-Lowering Drugs Segment, ($m, AGR%, CAGR%) 2017-2027
Table 9.1. Global Cholesterol-Lowering Drugs Market Forecast by Geography, ($m, AGR%, CAGR%) 2017-2027
Table 9.2. North America Cholesterol-Lowering Drugs Market Forecast by Country, ($m, AGR%, CAGR%) 2017-2027
Table 9.3. USA Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.4. Canada Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.5. Mexico Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.6. South America Cholesterol-Lowering Drugs Market Forecast, by Country ($m, AGR%, CAGR%) 2017-2027
Table 9.7. Brazil Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.8. Argentina Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.9. Paraguay Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.10. Bolivia Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.11. Rest of South America Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.12. European Cholesterol-Lowering Drugs Market Forecast by Country ($m, AGR%, CAGR%) 2017-2027
Table 9.13. France Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.14. Germany Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.15. UK Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.16. Spain Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.17. Italy Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.18. Rest of European Cholesterol-Lowering Drugs Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.19. Asia-Pacific Cholesterol-Lowering Drug Market Forecast by Country, ($m, AGR%, CAGR%) 2017-2027
Table 9.20. China Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.21. Japan Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.22. India Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.23. Australia Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.24. Thailand Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.25. Rest of Asia-Pacific Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.26. Rest of World Cholesterol-Lowering Drug Market Forecast by Country, ($m, AGR%, CAGR%) 2017-2027
Table 9.27. Middle East Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.28. Africa Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 9.29. Other Countries Cholesterol-Lowering Drug Market Forecast, ($m, AGR%, CAGR%) 2017-2027
Table 11.1. AstraZeneca Plc: Company Overview
Table 11.2.. AstraZeneca Plc: Product Portfolio
Table 11.3. AstraZeneca Plc: Recent Developments
Table 11.4. Merck & Co. Inc.: Company Overview
Table 11.5. Merck & Co. Inc.: Product Portfolio
Table 11.6. Merck & Co. Inc.: Recent Developments
Table 11.7. Pfizer Inc.: Company Overview
Table 11.8. Pfizer Inc.: Product Portfolio
Table 11.9. Pfizer Inc.: Recent Developments
Table 11.10. Kowa Company, Ltd.: Company Overview
Table 11.11. Kowa Company, Ltd.: Product Portfolio
Table 11.12. Kowa Company, Ltd.: Recent Developments
Table 11.13. Daiichi Sankyo Co., Ltd.: Company Overview
Table 11.14. AbbVie Inc.: Company Overview
Table 11.15. AbbVie Inc.: Product Portfolio
Table 11.16. Novartis AG: Company Overview
Table 11.17. Novartis AG: Product Portfolio
Table 11.18. Novartis AG: Recent Developments
Table 11.19. Sanofi S.A.: Company Overview
Table 11.20. Sanofi S.A.: Product Portfolio
Table 11.21. Sanofi S.A: Recent Developments
Table 11.22. Amgen Inc.: Company Overview
Table 11.23. Amgen Inc.: Product Portfolio
Table 11.24. Amgen Inc.: Recent Developments
Table 11.25. Bristol-Myers Squibb: Company Overview
Table 11.26. Bristol-Myers Squibb : Product Portfolio

List of Figures
Figure 1.1. Global Cholesterol-Lowering Drugs Market Segmentation Overview, 2015
Figure 2.1. Chemical Structure of Cholesterol, 2017
Figure 3.1. Global Cholesterol-Lowering Drugs Market Segments, by Type ($million) 2017-2027
Figure 3.2. Cholesterol-Lowering Drugs Market, by Statins and Fixed-Dose Combination, ($million) 2017-2027
Figure 3.3. Cholesterol-Lowering Drugs Market, by Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs, ($million) 2017-2027
Figure 3.4. Cholesterol-Lowering Drugs Market, by PCSK9 Inhibitors, ($million)2017-2027
Figure 3.5. Cholesterol-Lowering Drugs Market, by Novel Cholesterol-Lowering Drugs, ($million) 2017-2027
Figure 4.1. Global Cholesterol-Lowering Drugs Market Segments, by Type, Market Share (%), 2016
Figure 4.2. Global Cholesterol-Lowering Drugs Market Segments, by Type, Forecast ($million) 2017-2027
Figure 4.3. Global Statins and Fixed-Dose Combinations for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($million) 2017-2027
Figure 4.4. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($million) 2017-2027
Figure 4.5. Global PCSK9 Inhibitors for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($million) 2017-2027
Figure 4.6. Global Novel Cholesterol-Lowering Drugs for Cholesterol-Lowering Drugs Market Forecast, by Geography, ($million) 2017-2027
Figure 5.1. Global Statins and Fixed-Dose Combinations Market by Product ($million) 2017-2027
Figure 5.2. Global Statins and Fixed-Dose Combinations Market Share of Products (%), 2016
Figure 5.3. Global Crestor Market Forecast ($m) 2017-2027
Figure 5.4. Global Lipitor Market Forecast ($m) 2017-2027
Figure 5.5. Global Livalo Market Forecast ($m) 2017-2027
Figure 5.6. Global Lescol /Lescol XL Market Forecast ($m) 2017-2027
Figure 5.7. Global Zocor Market Forecast ($m) 2017-2027
Figure 5.8. Global Vytorin Market Forecast ($m) 2017-2027
Figure 5.9. Global Caduet Market Forecast ($m) 2017-2027
Figure 5.10. Global Others Market of Statins and Fixed-Dose Combinations Segment ($m) 2017-2027
Figure 6.1. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market by Product ($million) 2017-2027
Figure 6.2. Global Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Market Share of Products (%), 2016
Figure 6.3. Global Zetia Market Forecast ($m) 2017-2027
Figure 6.4. Global Welchol Market Forecast ($m) 2017-2027
Figure 6.5. Global Tricor Market Forecast ($m) 2017-2027
Figure 6.6. Global Others Market of the Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs Segment ($m) 2017-2027
Figure 7.1. Global PCSK9 Inhibitors Market Share of Products (%), 2016
Figure 7.2. Global PCSK9 Inhibitors Market by Product ($million) 2017-2027
Figure 7.3. Global Praluent Market Forecast, ($m) 2017-2027
Figure 7.4. Global Repatha Market Forecast, ($m) 2017-2027
Figure 7.5. Global RN316 Market Forecast, ($m) 2017-2027
Figure 7.6. Global Others Market of the PCSK9 Inhibitors Segment, ($m) 2017-2027
Figure 8.1. Global Novel Cholesterol-Lowering Drugs, Market Share of Products (%), 2016
Figure 8.2. Global Novel Cholesterol-Lowering Drugs Market by Product ($million) 2017-2027
Figure 8.3. Global Juxtapid Market Forecast, ($m) 2017-2027
Figure 8.4. Global Kynamro Market Forecast, ($m) 2017-2027
Figure 8.5. Global MK-089 Market Forecast, ($m) 2017-2027
Figure 8.6. Global Other Drugs Market of the Novel Cholesterol-Lowering Drugs Segment, ($m) 2017-2027
Figure 9.1. Global Cholesterol-Lowering Drugs Market Forecast by Geography, ($million) 2017-2027
Figure 9.2. Global Cholesterol-Lowering Drugs Market by Geography, Market Share (%), 2016
Figure 9.3. North America Cholesterol-Lowering Drugs Market Forecast by Country, ($million) 2017-2027
Figure 9.4. North America Cholesterol-Lowering Drugs Market by Country, Market Share (%), 2016
Figure 9.5. USA Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
Figure 9.6. The Average Blood Concentration of LDL-C and TC:HDL-C Ratio, Canada, 2012 to 2013
Figure 9.7. Canada Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
Figure 9.8. Mexico Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
Figure 9.9 South America Cholesterol-Lowering Drugs Market Forecast, by Country ($million) 2017-2027
Figure 9.10. South America Cholesterol-Lowering Drugs Market by Country, Market Share (%), 2016
Figure 9.11. Brazil Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
Figure 9.12. Argentina Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
Figure 9.13. Paraguay Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
Figure 9.14. Bolivia Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
Figure 9.15. Rest of South America Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
Figure 9.16. Europe Cholesterol-Lowering Drugs Market Forecast by Country($million) 2017-2027
Figure 9.17. Europe Cholesterol-Lowering Drugs Market by Country, Market Share (%), 2016
Figure 9.18. France Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
Figure 9.19. Germany Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
Figure 9.20. UK Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
Figure 9.21. Spain Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
Figure 9.22. Italy Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
Figure 9.23. Rest of Europe Cholesterol-Lowering Drugs Market Forecast ($m) 2017-2027
Figure 9.24. Asia-Pacific Cholesterol-Lowering Drug Market Forecast by Country, ($million) 2017-2027
Figure 9.25. Asia-Pacific Cholesterol-Lowering Drug Market by Country, Market Share (%), 2016
Figure 9.26. China Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
Figure 9.27. Japan Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
Figure 9.28. India Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
Figure 9.29. Australia Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
Figure 9.30. Thailand Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
Figure 9.31. Rest of Asia-Pacific Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
Figure 9.32. RoW Cholesterol-Lowering Drug Market Forecast by Country,($million) 2017-2027
Figure 9.33. Rest of World Cholesterol-Lowering Drug Market by Country, Market Share (%), 2016
Figure 9.34. Middle East Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
Figure 9.35. Africa Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
Figure 9.36. Other Countries Cholesterol-Lowering Drug Market Forecast ($m) 2017-2027
Figure 10.1. Porter’s Five Forces Analysis of the Cholesterol-Lowering Drugs Market, 2017-2027
Figure 11.1. AstraZeneca Plc, Revenue, ($million), 2012-2016
Figure 11.2. AstraZeneca Plc, Geographical Presence Share (%), 2016
Figure 11.3. Merck & Co. Inc., Revenue, ($million), 2012-2016
Figure 11.4. Merck & Co. Inc., Product Segments Share (%), 2016
Figure 11.5. Merck & Co. Inc., Geographical Presence Share (%), 2016
Figure 11.6. Pfizer Inc., Revenue, ($million), 2012-2016
Figure 11.7. Pfizer Inc., Product Segments Share (%), 2016
Figure 11.8 Pfizer Inc., Geographical Presence Share (%), 2016
Figure 11.9. Daiichi Sankyo Co., Ltd., Revenue, ($million), 2012-2016
Figure 11.10. Daiichi Sankyo Co., Ltd., Product Segments Share (%), 2016
Figure 11.11. Daiichi Sankyo Co., Ltd., Geographical Presence Share (%), 2016
Figure 11.12. AbbVie Inc., Revenue, ($million), 2012-2016
Figure 11.13. AbbVie Inc., Product Segments Share (%), 2016
Figure 11.14. AbbVie Inc., Geographical Presence Share (%), 2016
Figure 11.15. Novartis AG, Revenue, ($million), 2012-2016
Figure 11.16. Novartis AG, Product Segments Share (%), 2016
Figure 11.17. Novartis AG, Geographical Presence Share (%), 2016
Figure 11.18. Sanofi S.A., Revenue, ($million), 2012-2016
Figure 11.19. Sanofi S.A., Product Segments Share (%), 2016
Figure 11.20. Sanofi S.A., Geographical Presence Share (%), 2016
Figure 11.21. Amgen Inc., Revenue, ($million), 2012-2016
Figure 11.22. Amgen Inc., Product Segments Share (%), 2016
Figure 11.23. Amgen Inc., Geographical Presence Share (%), 2016
Figure 11.24. Bristol-Myers Squibb, Revenue, ($million), 2012-2016
Figure 11.25. Bristol-Myers Squibb, Product Segments Share (%), 2016
Figure 11.26. Bristol-Myers Squibb, Geographical Presence Share (%), 2016
Figure 12.1. World Cholesterol-Lowering Drug Market by Region: Revenues ($m), 2017-2027
Figure 12.2. World Cholesterol-Lowering Drugs Market Forecastb by Segment: Revenue ($m), 2017-2027
Figure 12.3. World Cholesterol-Lowering Drugs Market Driving Factors

【レポートのキーワード】

コレステロール低下薬

★調査レポート[コレステロール低下薬の世界市場2017-2027] ( Global Cholesterol-Lowering Drugs Market 2017-2027 : Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs / VGAIN7081119) 販売に関する免責事項
[コレステロール低下薬の世界市場2017-2027] ( Global Cholesterol-Lowering Drugs Market 2017-2027 : Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs / VGAIN7081119) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆